Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

Veer Bala Gupta; Eugene Hone; Steve Pedrini; James Doecke; Sid O'Bryant; Ian James; Ashley I Bush; Christopher C Rowe; Victor L Villemagne; David Ames; Colin L Masters; Ralph N Martins; AIBL Research Group

doi:10.1016/j.dadm.2017.04.003

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

Alzheimers Dement (Amst). 2017 Apr 23:8:60-72. doi: 10.1016/j.dadm.2017.04.003. eCollection 2017.

Authors

Veer Bala Gupta^{1

2}, Eugene Hone^{1

2}, Steve Pedrini^{1

2}, James Doecke³, Sid O'Bryant⁴, Ian James⁵, Ashley I Bush^{2

6}, Christopher C Rowe⁷, Victor L Villemagne^{6

7}, David Ames^{8

9}, Colin L Masters⁶, Ralph N Martins^{1

2

10}; AIBL Research Group

Affiliations

¹ School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
² Co-operative Research Centre for Mental Health, Carlton, Victoria, Australia.
³ CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Queensland, Australia.
⁴ Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA.
⁵ School of Engineering and Information Technology, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
⁶ The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia.
⁷ Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.
⁸ National Ageing Research Institute, Parkville, Victoria, Australia.
⁹ Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
¹⁰ School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia.

Abstract

Introduction: A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing.

Methods: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort.

Results: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P = .0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P = .0008).

Discussion: These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

Keywords: Alzheimer's disease; Biomarkers; Blood.